Review in Journal of diabetes research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Martha GulatiDepartment of Cardiology, Davis Women's Heart Center, Houston Methodist DeBakey Heart and Vascular Center, Houston, Texas, USA.ORCID https://orcid.org/0000-0003-0735-9756
Funding
UCLA Clinical and Translational Science InstituteUL1TR000124 · NCATS · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI DUBINETT, STEVEN M. · 2012 to 2015
$57.0M
The Microvascular Aging and Eicosanoids - Women's Evaluation of Systemic Aging Tenacity (MAE-WEST) ("You are never too old to become younger!") Specialized Center for Research Excellence (SCORE)U54AG065141 · NIA · CEDARS-SINAI MEDICAL CENTER · PI BAIREY MERZ, CATHLEEN NOEL, CHENG, SUSAN · 2020 to 2024
$8.7M
Women's Ischemia Syndrome EvaluationU01HL064829 · NHLBI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI KELSEY, SHERYL F. · 2001 to 2005
$3.9M
Women's Ischemia Syndrome Evaluation (WISE) - Mechanisms of Coronary Microvascular Dysfunction Leading to Pre-Heart Failure with Preserved Ejection Fraction (HFpEF)R01HL146158 · NHLBI · CEDARS-SINAI MEDICAL CENTER · PI BAIREY MERZ, CATHLEEN NOEL · 2019 to 2023
$3.7M
Women's Ischemia Syndrome Evaluation (WISE) Coronary Vascular DysfunctionR01HL090957 · NHLBI · CEDARS-SINAI MEDICAL CENTER · PI BAIREY MERZ, CATHLEEN NOEL, PEPINE, CARL J · 2008 to 2013
$3.5M
Whole-Heart Myocardial Blood Flow Quantification Using MRIR01HL124649 · NHLBI · CEDARS-SINAI MEDICAL CENTER · PI LI, DEBIAO · 2015 to 2018
$3.3M
Myocardial Steatosis in Women with Coronary Microvascular Dysfunction: Defining the Pathway to Heart Failure with Preserved Ejection Fraction (HFpEF)R01HL153500 · NHLBI · CEDARS-SINAI MEDICAL CENTER · PI WEI, JANET · 2021 to 2025
$3.2M
Behavioral Medicine and Cardiovascular Research TrainingT32HL069751 · NHLBI · HENRY M. JACKSON FDN FOR THE ADV MIL/MED · PI KRANTZ, DAVID S. · 2003 to 2007
$1.2M
Atherosclerosis, Immune Mediated Inflammation and Hypoestrogenemia in Young WomenK23HL127262 · NHLBI · CEDARS-SINAI MEDICAL CENTER · PI SHUFELT, CHRISANDRA LEE · 2016 to 2020
$988k
Magnetic Resonance Imaging for Global Atherosclerosis Risk AssessmentK23HL125941 · NHLBI · CEDARS-SINAI MEDICAL CENTER · PI WEI, JANET · 2016 to 2020
$985k
Cardiac Autonomic Function in WomenK23HL105787 · NHLBI · EMORY UNIVERSITY · PI MEHTA, PUJA KIRAN · 2012 to 2016
$813k
Hypertensive Disorders of Pregnancy: Pathways to Future Cardiovascular DiseaseK23HL151867 · NHLBI · THE CHRIST HOSPITAL · PI QUESADA, ODAYME · 2020 to 2024
$799k
Anita Dann Friedman Endowment in Women's Cardiovascular Medicine & ResearchCedars-Sinai Medical CenterErika Glazer Women's Heart Health ProjectGustavus and Louis Pfeiffer Research FoundationLadies Hospital Aid SocietyLinda Joy Pollin Women's Heart Health ProgramNCATS NIH HHS UL1TR000124NCRR NIH HHS MO1-RR00425NHLBI NIH HHS K23 HL105787NHLBI NIH HHS K23 HL125941NHLBI NIH HHS K23 HL127262NHLBI NIH HHS K23HL151867NHLBI NIH HHS N01-HV-068161NHLBI NIH HHS N01-HV-068162NHLBI NIH HHS N01-HV-068163NHLBI NIH HHS N01-HV-068164NHLBI NIH HHS R01 HL090957NHLBI NIH HHS R01 HL124649NHLBI NIH HHS R01 HL146158NHLBI NIH HHS R01 HL146158-04S1NHLBI NIH HHS R01 HL153500NHLBI NIH HHS R03 AG032631NHLBI NIH HHS T32 HL069751NHLBI NIH HHS U01 HL064829NHLBI NIH HHS U01 HL649141NHLBI NIH HHS U01 HL649241NHLBI NIH HHS U54 AG065141QMED, IncRobert NA. Winn Diversity in Clinical Trials Career Development AwardSociety for Women's Health ResearchU.S. Department of Defense PR161603
6 · The paper itself
Abstract
Cardiovascular disease (CVD) remains the leading global cause of mortality, with physical activity (PA) and inactivity playing a significant role in its prevalence and outcomes. PA has been shown to substantially reduce cardiovascular and cardiometabolic risk through mechanisms such as favorable cardiac remodeling, improved endothelial function, and enhanced metabolic regulation. This review explores the broad cardiovascular benefits of PA across both general and diabetic populations, highlighting its impact on reducing disease incidence, improving cardiac function, and lowering cardiovascular mortality. Various forms of PA-including aerobic, resistance, and flexibility and balance training-demonstrate differing but complementary roles in promoting cardiovascular health. Despite strong evidence and guideline endorsements, participation rates remain low, with fewer than a quarter of US adults meeting the minimum PA recommendations. Barriers to PA-personal, environmental, and health-related-remain significant and underaddressed. Enhanced patient education, clinician engagement, and tailored intervention strategies are essential to improve adherence and outcomes. Overall, PA is a critical, evidence-based strategy for reducing CVD risk.
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.